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The major aim of this study is to study the BORIS and CTCF genes expression 
in brain tumors by determines the relative quantification of expression by Real-Time 
RT -PCR analyses. The result in this study is vital as one of other new approaches for 
the diagnostic or prognostic brain tumour purposes. To investigate the expression of 
these genes' m.RNA, the samples of total RNA was prepared for each tumour sample. 
Intact total RNA with purity between 1.8 - 2.0 was used for synthesis of eDNA. In 
order to confirm the expression level of BORIS and CTCF gene, gene-specific primer 
were designed using sequence obtained from GenBank (Primer Express Software 
version 2.0 Apllied Biosystem). Real-Time RT-PCR analysis was conducted by 
measuring the given level of fluorescence as the number of cycle threshold (Cr ). These 
Cr values serve as indirect indicators of gene expression so that samples with high 
expression of a given gene will exhibit lower Cr value than samples showing low level 
of gene expression. A gene is considered differentially expressed if its relative 
expression is two-fold or greater. In this study, the results of Real-Time RT-PCR 
demonstrated that the expression level of the CTCF was significantly higher in tumor 
than in normal in 2.8 fold. However, there was no BORIS expression was detected 
either in tumor or normal sample. Even though this is only preliminary study due to 
restricted number of samples and also limited time given, however, we believe that by 
further this study will guide us to appreciate better the role of BORIS and CTCF genes 
in formation of brain tumor. 
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ABSTRAK 
Tujuan utama kajian ini adalah untuk mengkaji pengekspresan BORIS dan 
CTCF eli dalam tumor otak. dengan cara menentukan kuantiti relatifnya berdasarkan 
analisis oleh 'Real-Time RT -PCR'. Keputusan kajian ini penting kerana ia merupakan 
salah satu pendekatan terbaru dalam diagnostik dan prognostik penyakit tumor otak. 
Dalam menyiasat pengekspresan gen mRNA, sampel dari RNA total disediakan dari 
setiap sampel tumor. Hanya RNA total yang memiliki A2601280 di dalam julat 1.8 - 2.0 
akan digunakan untuk menghasilkan eDNA Untuk menentukan peringkat 
pengekspresan gen, primer spesifik-gen akan direka menggunakan jujukan yang 
diperolehi dari GenBank (Primer Express Software version 2.0 Apllied Biosystem). 
Analisis 'Real-Time RT-PCR' ini telah dijalankan dengan mengukur aras fluorescence 
yang ditunjukkan sebagai 'cycle threshold' (CT). Nilai CT ini berperanan sebagai 
petunjuk tidak langsung untuk pengekspresan gen. Oleh sebab itu, sampel yang 
memiliki pengekspresan gen yang tinggi akan mempamerkan nilai CT yang lebih 
rendah berbanding sampel yang memilik.i aras ekspressi gen yang rendah. Di dalam 
kajian ini, keputusan 'Real-Time PCR' menunjukkan bahawa aras pengekspresan untuk 
gen CTCF adalah lebih tinggi di dalam sampel tumor berbanding sampel normal 
sebanyak 2.8 kali. Walaupun kajian ini hanya sebagai saringan disebabkan oleh 
bilangan sampel yang agak terhad serta kekangan masa yang dialami, namun, kami 
percaya bahawa dengan meneruskan kajian ini dapat membawa kita untuk lebih 
memahami peranan BORIS dan CTCF di dalam pembentukan tumor otak. 
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CHAPTERl INTRODUCTION 
1.1 Introduction to BraiD Tumour 
Tumors of the central nervous system (CNS) are the second commonest form of 
cancer in children and the sixth commonest form in adult (Ironside et al., 2002) while 
glioblastoma multifonne type is (GBM) being the most malignant form of this disease 
(Tsuchiya et al., 2005). The biological behaviour of gliomas varies from slow-growing 
well-distinct tumors that are curable by excision to malignant invasive tumors that are 
uniformly fatal. While pathology has a major role to play in the management of patients 
with gliomas by providing a histological diagnosis and tumour grade, which are of 
major prognostic significance, however, molecular genetic studies have found loss of 
genetic material in many gliomas, with progressive losses identified with increasing 
tumour grade. For instance in oligodendrogliomas, loss of heterozygosity (LOH) on 
chromosomes 1 p and 19q is of therapeutic significance as a predictor of tumour 
response to chemotherapy (Colin et al., 2006). Besides, glioblastomas are highly 
malignant brain tumors and they have been described as one of the most deadly human 
cancers (Carteret al., 2008). 
There are two theoretical classifications of the condition exist: primary (de novo), 
which does not exhibit prior disease and secondary glioblastoma, which develops from 
a pre-existing glioma (Carter et al., 2008). Glioma can arise either spontaneously 
(primary glioma) or can progress from a lower to a higher grade of tumour (secondary 
glioma) (Colin et al., 2006). The complex accumulation of genetic mutations leading to 
each type of glioma (astrocytoma, oligodendroglioma, mixed oligoastrocytoma and 
glioblastomas) and to primary and secondary glioma of the same tissue type, are known 
to be very different These include increased expression of genes, reduced expression of 
genes and a LOH on chromosome arms (Carter et al., 2008). 
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However, the classifications of brain tumor can now be enhanced with new 
techniques for comprehensive molecular characterization. Advanced m 
diagnosis/prognosis by improved molecular profiling of brain tumors and identifying 
targets for novel and rational therapeutic approaches is indispensable nowadays. In 
order that, neurosurgeons and neuro-oncologists should be aware of these new 
developments so they can better advise and treat their patients (Boudreau et al, 2005). 
1.2 Statistic and prevalence of brain tumors in Malaysia 2003 
Based on the report release by National Cancer Registry (2003), there are 420 
cases of brain tumor were documented, comprising 2.4 % of male cancer and 1.6% of 
female cancer. The male: female ratio in tenns of incidence for Peninsular Malaysia 
was 1.6: 1. Rates of brain tumour rose progressively with age for males and female but 
slightly decrease at 70 years old people. Based on the table 1.1, there was a steeper rise 
in incidence after the age 45 years for males and 55 years for females, with a 
progressive divergence of the curves for the two sexes. 
Table 1.1 Brain and Other Nervous System Age specific Cancer Incidence per 
100,000 populations (CR), by sex, Peninsular Malaysia 2003 
Male Female 
Age, year No. % CR No. % CR 
0-9 33 13.3 1.5 32 14.6 1.5 
10-19 38 15.3 1.9 31 14.2 1.6 
20-29 34 13.7 2.2 26 11.9 1.7 
30-39 43 17.3 3.2 36 16.4 2.7 
40-49 33 13.3 2.9 26 11.9 2.3 
50-59 26 10.4 3.5 36 16.4 5 
60-69 29 11.6 7.3 22 10.0 5.7 
70+ 13 5.2 6.0 to 4.6 3.7 
4 
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Figure 1.1 Age specific Cancer (Brain and Other Nervous System) Incidence per 
100,000 populations (CR), by sex, Peninsular Malaysia 2003. 
(Second Report of the National Cancer Registry Cancer Incidence in Malaysia 2003) 
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1.2.1 Incidence of brain tumor (HUSM) 
The retrospective study of the epidemiology and prognostic factors of brain 
tumors was carried out at Hospital Universiti Sains Malaysia (HUSM) in Kelantan. 
HUSM serve as a regional referral for both Kelantan and Terengganu states. The crude 
incidence of brain tumor in this study was 0.44 per 100.000 population per year. Yusoff 
et. al., (2005) have reported there are slightly significant difference of brain tumor 
incidence between the sexes. The incidence of brain tumors in general was more 
common in males than females. This finding was similar to that of Institute of 
Neurology in Kuala Lumpur (ratio 2:1) and mainly studies on primary neoplasms of the 
brain. Seventy patients with brain tumors confirmed by CT scan were admitted to 
HUSM during the study period. 93% of patients were Malays and 71% belonged to the 
low socio-economic group. The distribution of brain tumors is shown in Table 1.2. Out 
the 70 patients admitted over the study period, 49 had histopathological confirmation of 
type of brain tumour (Table 1.2). 96% were primary brain tumors and the remainder 
(4%) were metastatic cancer. Neuroglial tumors were the most common (35%), 
followed by meningioma (33%), medulloblastoma (12%) and schwannomas (6%). In 
children younger than 15 years of age, medulloblastoma was the most common variety 
encountered (41.7%), followed by other specific tumors (18.3%), astrocytoma (8.3%), 
and meningioma (8.3%). 
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Table 1.2 Distribution of brain tumors based on type of tumor and age in HUSM 
Type of tumor Age 
Number < 15 years 15 -44 >45 
years years 
Astrocytoma 7 (10%) 4 (5.7%) 2 (2.9%} 1 (1.4%}_ 
Oligodendro- glioma 
2 (2.9%) 0(0%) 2_{2.9%) 0(0%) 
Glioblastoma multiforme 
8(11.4o/o} 1 (1.4%) 6 (8.6%) 1 (1.4%) 
Meningioma 16 (22.9%) 1 (1.4%) 6 (8.6%) 1 (1.4%) 
Medulloblastoma 16 (22.9%) 1 (1.4%) 9 (12.9%) 6 {8.6%) 
Nerve sheat tumour 
3 (4.3%) 0{0%) 2 (2.9%) 1 (1.4%) 
Other specified tumour 
7 (lOo/o}_ 1_(1.4%) 5 (7.1%) 1 {1.4%) 
Not 
Microscopically 21 (30%) 4 (5.7%) 10 (14.3%) 7 (10%) 
confirmed 
Total 70 (100%) 16_(22.6%) 37 (52.9%) 17 (24.2%) 
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1.3 Tbe Classification of Brain Tumour 
1.3.1 Primary Malignant Brain Tumors 
A primary malignant brain tumor is one that originates in the brain itself. 
Although primary brain tumors often shed cancerous cells to other sites in the central 
nervous system (the brain or spine), they rarely spread to other parts of the body. 
The degree of malignancy in brain glioma (Bredel and Pollack, 1999) decides 
the treatment, because if it is grade I or II according to Kemohan, the success rate of 
operation is satisfactory; otherwise, if it is grade III or IV, there will be high surgical 
risk and poor life quality after surgery which must be taken into account before any 
further decision (Wang et al., 2000). 
Brain tumors are generally named and classified according to the following: 
• The normal brain cells from which they originate, or 
• The location in which the cancer develops 
The biologic diversity of these tumors, however, makes classification difficult, 
and some experts believe that categories that are more specific are needed. 
The World Health Organization (WHO) classification (2000), groups these CNS 
tumors into five main types (Kleihues and Sobin, 2000): tumors of neuroepithelial 
tissue, tumors of peripheral nerve, tumors of the meninges, lymphomas and 
haematopoietic neoplasms, and germ cell tumors. Of these, the commonest group is the 
tumors of neuroepithelial tissue, which are dominated by the group of tumors known as 
gliomas. 
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1.3.2 Categories of Primary Glioma Brain Tumors by Cell Types 
About half of all primary brain tumors are known collectively as gliomas. They 
are cancerous forms of glial cells, the building-block cells of the connective, or 
supportive, tissue in the central nervous system. There are several glial cells types from 
which gliomas form. Their names are: 
Astrocytomas represent the most common type of glioma. They develop from 
the supporting cells of the brain, which are star-shaped glial cells called astrocytes. 
Functions of normal astrocytes are to provide nutrients, support, and insulation for 
nerve cells and are one of the primary neurologic cells in the body. The malignant 
astrocytomas called glioblastomas account for 23% of brain tumors and are the most 
common ones (Terada eta/., 2002). 
Oligodendrogliomas represent 4% of all primary brain tumors (McDonald et al., 
2005). They develop from glial cells called oligodendroglia, which are the cells that 
form the myelin sheath (covering insulation) of the nerve fibers within the brain. They 
occur most often in young and middle-aged adults but are also seen in children. The 
most common site of oligodendrogliomas is in the brain's cerebral hemisphere. 
Ependymoma is a type of glioma that arises from the ependymal cells lining the 
ventricles within the brain and the central canal of the spinal cord. Ependymomas most 
often affect children, representing 10% of all childhood brain tumors. In adults, they 
occur most commonly in the spinal cord (lwadate et al., 2004). 
9 
1.3.3 Categories of Braio Tumors by Location 
Some brain tumors are categorized by their location in the brain. Such tumors 
often contain gliomas but are also frequently a mixture of different cell types. 
Meningiomas develop from meninges, the thin, protective membranes that 
cover the brain and spinal cord. They account for approximately 25% of all brain 
tumors (Marosi et al., 2008). They occur more often in women than in men. Most grow 
very slowly, and the majority of people who have them never know they are present. 
Since this tends to be a slow growing tumor, it can be quite large before being 
diagnosed. 
Medulloblastoma are primitive neuroectodermal tumors (PNEn that arise in the 
cerebellum. They are the most common malignant brain tumor among children, 
representing more than 25% of all childhood brain tumors (Maher et al., 2001 ). This is 
an aggressive and invasive tumor, which frequently spreads throughout the central 
nervous system by the spinal fluid. Although medulloblastomas usually occur m 
children, with boys more often being affected than girls, they also occur in adults. 
Brain stem gliomas develop in the lowest portion of the brain. The brain stem 
connects the cerebrum (the higher centers of the brain) to the spinal cord. The brain 
stem is thought to be the primitive brain because it controls the most basic functions. A 
stroke affecting the brain stem is potentially life threatening since this area of the brain 
controls functions such as breathing and instructing the heart to beat. Besides, brain 
stem stroke may also cause double vision, nausea and loss of coordination. 
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1.4 Involvement of BORIS and CTCF Gene in the Epigenetic of Normal 
Biology and Cancer 
CTCF is a ubiquitous, preserved and highly versatile 11 Zn finger (ZF) factor. 
There are identified more than 20 genes ofCTCF target sequences (CTSs). The distinct 
feature of CTCF is its ability to bind different CTCF-target sites by utilization of 
different ZFs (K.lenova et al., 2002). Recent identified of CTCF paralogue, BORIS (for 
brother of the regulator of imprinted sites) represent a unique pair of protein that share 
the same DNA-binding domain. While CTCF is ubiquitous, highly versatile and has 
features of a tumor suppressor gene, BORIS is expressed only in male germ cell 
differentiation, but expression in BORIS-negative cell promote cell growth that lead to 
transformation. Thus, it is activated high proportion in cancer cell and has a feature of 
oncogene. 
1.5 The Structure and Function of the CTCF Protein 
CTCF is a ubiquitous 11-zinc-finger protein that plays a role in gene silencing 
or activation, chromatin insulation and genomic imprinting. The CTCF gene has been 
mapped to the chromosome band 16q22.1 that shows frequent of LOH in breast cancer 
(Frengen et al, 2000). CTCF encodes a DNA-binding 11-zinc-finger protein that shows 
a highly versatile function and multiple DNA sequence specificity (Filippova et al., 
1998). CTCF is a widely expressed transcription factor that is involved in different 
aspects of gene regulation including promoter activation (V ostrov and Quitschk.e, 1997) 
and repression (Filippova et al., 1996), hormone-responsive gene silencing (Burcin et 
al., 1997), methylation-dependent chromatin insulation and genomic imprinting 
(Filippova et al., 2002). In addition, it has been demonstrated that CTCF can inhibit cell 
growth and induce cell cycle arrest at multiple stages (Rasko et al., 2001 ). The tumour 
suppressor role of CTCF was suspected because of its involvement in regulating the 
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expression of some genes that are directly implicated in cancer (i.e., MYC, IGF2, p53, 
P27, p19/ARF and BRCAl) (Klenova et al., 2002), its cell growth inhibitory effect and 
its genetic mapping to 16q22.1. In addition, some tumour-specific mutations have been 
detected in some tumors including breast cancer (Filippova et al., 2002). 
1.6 The Structure and Function of the BORIS Protein 
BORIS is a paralogue of the 11 zinc-fmger transcription factor, CTCF. 
Although the zinc-fmger domain of BORIS protein has remarkable homology to the 
CTCF zinc-finger domain; but the N- and C-terminal domains of BORIS are different 
from these domains ofCTCF (Ghochikyan et al., 2007). BORIS is normally expressed 
only in spermatocytes in the testis; however, it is abnormally expressed in various 
tumors and cancer cell lines. 
Scanlan et al., 2004, BORIS has been reported to be classified as a protein 
belonging to the cancer testis antigen (CTA) family. The CTA gene products exhibit 
highly tissue-restricted expression and are immunogenic in cancer patients (Scanlan et 
al., 2004 ). Though the function of the majority of the CT As is still unknown; yet, some 
CT As are thought to be implicated in the regulation of gene expression and others may 
control gametogenesis (Old, 2001). On the other hand, The CTAs are attractive targets 
for developing cancer-specific immunotherapy because of their highly restricted 
expression in normal tissues and broad expression in a wide range of tumors (Chitale et 
al., 2005). 
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1. 7 Comparison Structure of CTCF and BORIS Gene 
Since BORIS is a paralogue of CTCF, thus, it shares the same exon encoding 
the 11 ZF-domain as mammalian CTCF genes, and therefore interacts with similar cis 
elements, but encodes amino and carboxy termini distinct from those in CTCF 
(Loukinov et al., 2002). For that reason, the antagonistic features of these two gene 
siblings are underscored by showing that while CTCF over expression blocks cell 
proliferation; expression of BORIS in normally BORIS-negative cells promotes cell 
growth that can lead to transformation (Klenova et al., 2002). Consequently, the sibling 
competition occasioned by aberrant expression of BORIS in cancer may interfere with 
normal functions of CTCF including growth suppression, and contribute to epigenetic 
dysregulation, which is a conunon feature in human cancer (Klenova et al., 2002). 
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Figure 1.2 Structure of CTCF. CTCF is the first example of a true 'multivalent' 
transcriptional factor with multiple DNA-binding sequence specificity. 
·. 
Multiple sequence specificity is achieved through combination utilization of different 
group of CTCF zinc fingers 
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1.8 Role of BORIS Gene in Tumor Development 
The human BORIS gene maps to chromosome 20q13.2 (Loukinov et al., 2002). 
However, this chromosome region is often amplified in many cancers and is believed to 
contain a dominant immortalising or transforming gene(s) (Tanner et al., 1994). So far, 
recent reports show that BORIS is a downstream regulator of cancer-testis genes: 
expression of BORIS in normal cells leads to derepression of cancer-testis genes 
MAGE-At, NY-ES0-1 and others (Hong et al., 2005). As a results of CTCF and 
BORIS are expressed in a mutually exclusive manner during male germ-line 
development (Loukinov et al., 2002); thus, suggesting that BORIS may be important 
for epigenetic reprogramming occurring during development in these cells. Definitely, 
BORIS has been implicated in the initiation of a series of methylation events at the 
imprinting control regions, in the area of the CTCF-IBORIS-binding sites, which may 
be significant for cancer development (Jelinic et al., 2006). CTCF and BORIS thus 
present a uniquely paired set of genes with dysfunction contributing to the pathogenesis 
of multiple tumor types. 
An interesting question is why and how BORIS itself is activated. Recent 
reports reveal that both genetic and epigenetic mechanisms are likely to be implicated 
in this process. Thus, DNA methylation, functional p53 and CTCF play an important 
role in the negative regulation of the promoters of the BORIS gene (Renaud et al., 
2007). Because of demethylation of DNA, knockout of CTCF and absence of 
functional p53, they lead to strong activation of BORIS. To date, the research efforts of 
several laboratories are currently focused on uncovering the details of the molecular 
mechanisms of activation and regulation of BORIS. 
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